Frontiers in Pharmacology (Aug 2021)
Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
- Yiting Sun,
- Yiting Sun,
- Yiting Sun,
- Yiting Sun,
- Liqing Jiang,
- Liqing Jiang,
- Liqing Jiang,
- Liqing Jiang,
- Ti Wen,
- Ti Wen,
- Ti Wen,
- Ti Wen,
- Xiaoyu Guo,
- Xiaoyu Guo,
- Xiaoyu Guo,
- Xiaoyu Guo,
- Xinye Shao,
- Xinye Shao,
- Xinye Shao,
- Xinye Shao,
- Hui Qu,
- Hui Qu,
- Hui Qu,
- Hui Qu,
- Xi Chen,
- Xi Chen,
- Xi Chen,
- Xi Chen,
- Yujia Song,
- Yujia Song,
- Yujia Song,
- Yujia Song,
- Fang Wang,
- Fang Wang,
- Fang Wang,
- Fang Wang,
- Xiujuan Qu,
- Xiujuan Qu,
- Xiujuan Qu,
- Xiujuan Qu,
- Zhi Li,
- Zhi Li,
- Zhi Li,
- Zhi Li
Affiliations
- Yiting Sun
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Yiting Sun
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Yiting Sun
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Yiting Sun
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Liqing Jiang
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Liqing Jiang
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Liqing Jiang
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Liqing Jiang
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Ti Wen
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Ti Wen
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Ti Wen
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Ti Wen
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Xiaoyu Guo
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Xiaoyu Guo
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xiaoyu Guo
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Xiaoyu Guo
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Xinye Shao
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Xinye Shao
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xinye Shao
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Xinye Shao
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Hui Qu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Hui Qu
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Hui Qu
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Hui Qu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Xi Chen
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Xi Chen
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xi Chen
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Xi Chen
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Yujia Song
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Yujia Song
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Yujia Song
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Yujia Song
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Fang Wang
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Fang Wang
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Fang Wang
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Fang Wang
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- Zhi Li
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
- Zhi Li
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Zhi Li
- Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, China
- Zhi Li
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, China
- DOI
- https://doi.org/10.3389/fphar.2021.670900
- Journal volume & issue
-
Vol. 12
Abstract
The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to provide a comprehensive bibliometric analysis of the literature on anti-PD1/PDL1 from three perspectives including molecular mechanisms, randomized clinical trials (RCT), and meta-analysis, thus producing a knowledge map reflecting the status of the research, its historical evolution, and developmental trends in related research from 2000 to 2020. We included 11,971, 191, and 335 documents from the Web of Science Core Collection database, respectively, and adopted various bibliometric methods and techniques thereto. The study revealed the major research themes and emergent hotspots based on literature and citation data and outlined the top contributors in terms of journals and countries. The co-occurrence overlay of keywords and terms pertaining to the PD1/PDL1 molecule reflected the progress from the discovery of the PD1/PDL1 molecule to the clinical application of anti-PD1/PDL1. Immune-related adverse events (irAEs) formed a unique cluster in the term co-occurrence analysis of meta-analysis. The historical direct citation network of RCT indicated the development and transformation of cancers and therapy strategies. irAEs and the strategies of combination therapy might become a future focus of research in this cognate area. In summary, the bibliometric study provides a general overview of the landscape on anti-PD1/PDL1 research, allowing researchers to identify the potential opportunities and challenges therein.
Keywords